The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Rakhmatulina M.R.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Tarasenko E.N.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology

Urogenital candidiasis: modern concepts of the disease species structure and anti-mycotic resistance of the genus’ Candida fungi

Authors:

Rakhmatulina M.R., Tarasenko E.N.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2021;20(2): 7‑14

DOI: 10.17116/klinderma2021200217

Read: 4632 times

Download PDF (RU)
Contact the author
Table of contents

UROGENITAL CANDIDIASIS: MODERN CONCEPTS OF THE DISEASE SPECIES STRUCTURE AND ANTI-MYCOTIC RESISTANCE OF THE GENUS’ CANDIDA FUNGI
UROGENITAL CANDIDIASIS: MODERN CONCEPTS OF THE DISEASE SPECIES STRUCTURE AND ANTI-MYCOTIC RESISTANCE OF THE GENUS’ CANDIDA FUNGI

To cite this article:

Rakhmatulina MR, Tarasenko EN. Urogenital candidiasis: modern concepts of the disease species structure and anti-mycotic resistance of the genus’ Candida fungi. Russian Journal of Clinical Dermatology and Venereology. 2021;20(2):7‑14. (In Russ.)
https://doi.org/10.17116/klinderma2021200217

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The problem of urogenital candidiasis’ treatment does not lose its relevance due to high morbidity rates in the population, an increase in the number of chronic recurrent forms of the disease and an increase in the level of anti-mycotic resistance of Candida fungi. The article presents modern data on the epidemiology and species structure of urogenital candidiasis, the frequency of detection of various types of the genus’ Candida fungi in recent years. When analyzing the data a pronounced dynamics was established towards an increase in the role of non-albicans Candida species in the development of genitourinary system’s candida lesions that necessitates the optimization of the patients’ tactics managing with this pathology and performing the species identification of Candida, especially in cases of recurrent disease’s course. The data of studying the mechanisms of bio-membrane formation and their role in the pathogenesis of candida infection are systematized. The main mechanisms of the yeast-like fungi resistance formation to anti-mycotic drugs are stated. The results of foreign and domestic scientific studies devoted to the study of indicators of antifungal resistance of Candida albicans and non-albicans species are analyzed. The analysis of the studied publications demonstrates the heterogeneous sensitivity of various Candida species to anti-mycotic drugs, as well as an increase in recent years in the detection of Candida strains’ resistant to azole drugs. The presence of Candida non-albicans strains and other opportunistic fungi is an important factor in the choice of treatment regimen and presents a major challenge to empiric therapy strategies.

Keywords:

urogenital candidiasis
vulvovaginal candidiasis
Candida albicans
Candida non-albicans
antimycotic resistance

Authors:

Rakhmatulina M.R.

State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Tarasenko E.N.

Moscow Research and Practical Center for Dermatovenereology and Cosmetology

Received:

24.07.2020

Accepted:

25.01.2021

Close metadata

References:

  1. Sobel JD. Pathogenesis of Recurrent Vulvovaginal Candidiasis. Current Infectious Disease Reports. 2002;4(6):514-519.  https://doi.org/10.1007/s11908-002-0038-7
  2. Zarochenceva NV, Belaya YuM. The problem of urogenital candidiasis in women in the modern world. RMJ. Mat’ i ditya. 2016;24(15):976-981. (In Russ.).
  3. Malova IO, Kuznetsova YA. Natamycin in the treatment of chronic recurrent vulvovaginal candidiasis associated with intestinal candidiasis. Meditsinskiy sovet. 2018;13:109-113. (In Russ.). https://doi.org/10.21518/2079-701X-2018-13-109-113
  4. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. American Journal of Obstetrics and Gynecology. 1998;178(2):203-210.  https://doi.org/10.1016/s0002-9378(98)80001-x
  5. Kira EF. Combined therapy of infectious diseases of female genitals. Ginekologiya. 2010;12(1):26-29. (In Russ.).
  6. Belikova ZF, Kastueva NZ, Tsallagova LV. Complex therapy of urogenital candidosis in women of fertil age in accordance with vaginal microbiocenosis. Kubanskij nauchnyj medicinskij vestnik. 2014;144(2):24-28. (In Russ.).
  7. Mezhevitinova EA, Abakarova PR, Pogosjan ShM. Use of fluconazole in women of reproductive age with vulvovaginal candidiasis. Medicinskij sovet. 2018;13:96-102. (In Russ). https://doi.org/10.21518/2079-701X-2018-13-96-102
  8. Amirova VR. Characteristics of Candida infection in newborns of high perinatal risk groups. Rossijskij pediatricheskij zhurnal. 2002;1:12-14. (In Russ).
  9. Bebneva TN, Dikke GB. Current features of vulvovaginal candidiasis and selection of rational therapy in pregnant and nonpregnant women. RMJ. Mat’ i ditya. 2018;1:49-56. (In Russ). https://doi.org/10.32364/2618-8430-2018-1-1-49-56
  10. Loszly M. IL-12 and IFN-Y deficiencies in human neonates. Pediatric Research. 2001;49(3):316.  https://doi.org/10.1203/00006450-200103000-00002
  11. Sergeev AYu, Malikov VE, Zharikov NE. Etiologiya vaginal’nogo kandidoza i problema ustojchivosti k antimikotikam. Seriya 4 «Medicinskaya mikologiya». M.: Obshcherossijskaya obshchestvennaya organizaciya «Obshchestvennaya nacional’naya akademiya mikologii»; 2001. (In Russ).
  12. Ankirskaya AS, Muraveva VV, Mironova TG, Koroleva TE, Lyubasovskaya LA, Karapetyan TE, Bayramova GR. Genital candidiasis in the structure of opportunistic vaginal infections. Principles of laboratory diagnostics and the importance of monitoring the sensitivity of fungi to antimicotics. Akusherstvo i ginekologiya. 2009;5:31-37. (In Russ).
  13. Veselov AV, Multykh IG, Klyasova GA, Agapova ED, Krechikova OI, Klimko NN, Dmitrieva NV, Ilina VN, Rozanova SM, Kozlov SN. Epidemiology of candidiasis pathogens and their sensitivity to azoles: results of the ARTEMIS DISK study in Russia. Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya. 2005;7(1):68-76. (In Russ.).
  14. Corsello SA, Spinillo G, Osnengo C, Penna S, Guaschino A, Beltrame N, Festa A. An epidemiological survey of vulvovaginal candidiasis in Italy. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2003; 110(1):66-72.  https://doi.org/10.1016/s0301-2115(03)00096-4
  15. Holland J, Young ML, Lee O, C-A Chen S. Vulvovaginal carriage of yeasts other than Candida albicans. Sexually Transmitted Infections. 2003;79(3):249-250.  https://doi.org/10.1136/sti.79.3.249
  16. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. Journal of Clinical Microbiology. 2005;43(5):2155-2162. https://doi.org/10.1128/JCM.43.5.2155-2162.2005
  17. Arzeni D, Del Poeta M, Simonetti O, Offidani AM, Lamura L, Balducci M, Cester N, Giacometti A, Scalise G. Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. European Journal of Epidemiology. 1997;13(4):447-450.  https://doi.org/10.1023/a:1007366722235
  18. Vermitsky JP, Self MJ, Chadwick SG, Trama JP, Adelson ME, Gygax SE. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. Journal of Clinical Microbiology. 2008;46(4):1501-1503. https://doi.org/10.1128/JCM.02485-07
  19. Ankirskaya AS, Muraveva VV, Fursova SA, Mironova TG, Koroleva TE. Monitoring of the species composition and sensitivity to antimycotics of yeast-like fungi isolated from the vagina of women of reproductive age. Klinicheskaya mikrobiologiya i antimikrobnaya himioterapiya. 2006;8(1):87-95. (In Russ.).
  20. Pfaller MA, Hazen KC, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. Journal of Clinical Microbiology. 2004;42(8):3607-3612. https://doi.org/10.1128/JCM.42.8.3607-3612.2004
  21. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, Bille J, Chang S-C, Martins M, Duse A, Dzierzanowska D, Ellis D, Finquelievich J, Gould I, Gur D, Hoosen A, Lee K, Mallatova N, Mallie M, Peng NG, Petrikos G, Santiago A, Trupl J, Abeele M, Wadula J, Zaidi M; the Global Antifungal Surveillance Group. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagnostic Microbiology and Infectious Disease. 2010;67(2):162-171.  https://doi.org/10.1016/j.diagmicrobio.2010.01.002
  22. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM Fu W, Colombo AL, Rodriguez-Noriega E; Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. Journal of Clinical Microbiology. 2007; 45(6):1735-1745. https://doi.org/10.1128/JCM.00409-07
  23. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A; the Global Antifungal Surveillance Group. Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. Journal of Clinical Microbiology. 2008;46(2): 515-521.  https://doi.org/10.1128/JCM.01915-07
  24. Sherry L, Kean R, McKloud E, O’Donnell LE, Metcalfe R, Jones BL, Ramage G. Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients are Heterogeneous and Insensitive to Fluconazole. Antimicrobial Agents and Chemotherapy. 2017;61(9):e01065-17.  https://doi.org/10.1128/AAC.01065-17
  25. Mendling W. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses. 2015;58(1):1-15.  https://doi.org/10.1111/myc.12292
  26. Fornari G, Vicente VA, Gomes RR, Muro MD, Pinheiro RL, Ferrari C, Herkert PF, Takimura M, de Carvalho NS, Queiroz-Telles F. Susceptibility and molecular characterization of Candida species from patients with vulvovaginitis. Brazilian Journal of Microbiology. 2016;47(2):373-380.  https://doi.org/10.1016/j.bjm.2016.01.005
  27. Zheltikova TM. Monitoring of resistance of clinical strains of Candida yeast to fluconazole (a brief review of the literature). Medicinskij sovet. 2017;2:70-74. (In Russ). https://doi.org/10.21518/2079-701X-2017-2-70-74
  28. Colombo AL, Júnior JNA, Guinea J. Emerging multidrug-resistant Candida species. Current Opinion in Infectious Diseases. 2017;30(6):528-538.  https://doi.org/10.1097/QCO.0000000000000411
  29. Chen PY, Chuang YC, Wu UI, Sun HY, Wang JT, Sheng WH, Lo HJ, Wang HY, Chen YC, Chang SC. Clonality of Fluconazole-Nonsusceptible Candida tropicalis in Bloodstream Infections, Taiwan, 2011–2017. Emerging Infectious Diseases. 2019;25(9):1660-1667. https://doi.org/10.3201/eid2509.190520
  30. Gulati M, Nobile CJ. Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes and Infection. 2016;18(5):310-321.  https://doi.org/10.1016/j.micinf.2016.01.002
  31. Cavalheiro M, Teixeira MC. Candida Biofilms: Threats, Challenges, and Promising Strategies. Frontiers in Medicine. 2018;5:28.  https://doi.org/10.3389/fmed.2018.00028
  32. Lohse MB, Gulati M, Johnson AD, Nobile CJ. Development and regulation of single- and multi-species Candida albicans biofilms. Nature Reviews. Microbiology. 2018;16(1):19-31.  https://doi.org/10.1038/nrmicro.2017.107
  33. Obisesan OJ, Olowe OA, Taiwo SS. Phenotypic Detection of Genitourinary Candidiasis among Sexually Transmitted Disease Clinic Attendees in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria. Journal of Environmental and Public Health. 2015;2015:401340. https://doi.org/10.1155/2015/401340
  34. Nobile CJ, Johnson AD. Candida albicans Biofilms and Human Disease. Annual Review of Microbiology. 2015;69:71-92.  https://doi.org/10.1146/annurev-micro-091014-104330
  35. Soll DR, Daniels KJ. Plasticity of Candida albicans Biofilms. Microbiology and Molecular Biology Reviews: MMBR. 2016;80(3):565-595.  https://doi.org/10.1128/MMBR.00068-15
  36. Moraes DC, Ferreira-Pereira A. Insights on the anticandidal activity of non-antifungal drugs. Journal de Mycologie Medicale. 2019;29(3):253-259.  https://doi.org/10.1016/j.mycmed.2019.07.004
  37. Crump JA, Collignon PJ. Intravascular catheter-associated infections. European Journal of Clinical Microbiology and Infectious Diseases. 2000; 19(1):1-8.  https://doi.org/10.1007/s100960050001
  38. Kojic EM, Darouiche RO. Candida infections of medical devices. Clinical Microbiology Reviews. 2004;17(2):255-267.  https://doi.org/10.1128/cmr.17.2.255-267.2004
  39. Dominic RM, Shenoy S, Baliga S. Candida biofilms in medical devices: evolving trends. Kathmandu University Medical Journal (KUMJ). 2007;5(3): 431-436. 
  40. Dongari-Bagtzoglou A, Kashleva H, Dwivedi P, Diaz P, Vasilakos J. Characterization of mucosal Candida albicans biofilms. PLoS One. 2009;4(11): e7967. https://doi.org/10.1371/journal.pone.0007967
  41. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL, Noverr MC. Candida albicans forms biofilms on the vaginal mucosa. Microbiology. 2010;156(12): 3635-3644. https://doi.org/10.1099/mic.0.039354-0
  42. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR, Johnson AD. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell. 2012;148(1-2):126-138.  https://doi.org/10.1016/j.cell.2011.10.048
  43. Woodburn KW, Clemens LE, Jaynes J, Joubert LM, Botha A, Nazik H, Stevens DA. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. Antimicrobial Agents and Chemotherapy. 2019;63(11): e02690-18.  https://doi.org/10.1128/AAC.02690-18
  44. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clinical Microbiology Reviews. 2010;23(2):253-273.  https://doi.org/10.1128/CMR.00076-09
  45. Flowers SA, Colón B, Whaley SG, Schuler MA, Rogers PD. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrobial Agents and Chemotherapy. 2015;59(1):450-460.  https://doi.org/10.1128/AAC.03470-14
  46. Alizadeh F, Khodavandi A, Zalakian S. Quantitation of ergosterol content and gene expression profile of ERG11 gene in fluconazole-resistant Candida albicans. Current Medical Mycology. 2017;3(1):13-19.  https://doi.org/10.29252/cmm.3.1.13
  47. Wu Y, Li C, Wang Z, Gao J, Tang Z, Chen H, Ying C. Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals. Medical Mycology. 2018;56(6):687-694.  https://doi.org/10.1093/mmy/myx099
  48. Malova IO, Petrunin DD. Natamycin Is an antifungal agent of the polyene macrolide class with unusual properties. Vestnik dermatologii i venerologii. 2015;3:161-184. (In Russ.).
  49. te Welscher YM, van Leeuwen MR, de Kruijff B, Dijksterhuis J, Breukink E. Polyene antibiotic that inhibits membrane transport proteins. Proceedings of the National Academy of Sciences of the United States of America. 2012;109(28): 11156-11159. https://doi.org/10.1073/pnas.1203375109
  50. Perlin DS. Echinocandin Resistance in Candida. Clinical Infectious Diseases. 2015;61(6):612-617.  https://doi.org/10.1093/cid/civ791
  51. Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathogens and Disease. 2016;74(4):ftw018. https://doi.org/10.1093/femspd/ftw018
  52. Negri M, Silva S, Breda D, Henriques M, Azeredo J, Oliveira R. Candida tropicalis biofilms: effect on urinary epithelial cells. Microbial Pathogenesis. 2012;53(2):95-99.  https://doi.org/10.1016/j.micpath.2012.05.006
  53. Fernandes T, Silva S, Henriques M. Effect of Voriconazole on Candida tropicalis Biofilms: Relation with ERG Genes Expression. Mycopathologia. 2016; 181(9-10):643-651.  https://doi.org/10.1007/s11046-016-0023-6
  54. Fonseca E, Silva S, Rodrigues CF, Alves CT, Azeredo J, Henriques M. Effects of fluconazole on Candida glabrata biofilms and its relationship with ABC transporter gene expression. Biofouling. 2014;30(4):447-457.  https://doi.org/10.1080/08927014.2014.886108
  55. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia. 2001; 151(1):5-10.  https://doi.org/10.1023/a:1010909504071
  56. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C, Horowitz B, Thron J V, Edwards L, Panzer H. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. The New England Journal of Medicine. 2004;351(9):876-883.  https://doi.org/10.1056/NEJMoa033114
  57. Sobel JD, Zervos M, Reed BD, Hooton D, Soper D, Nyirjesy P, Heine MW, Willems J, Panzer H. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrobial Agents and Chemotherapy. 2003;47(1):34-38.  https://doi.org/10.1128/aac.47.1.34-38.2003
  58. Bauters TG, Dhont MA, Temmerman MI, Nellis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. American Journal of Obstetrics and Gynecology. 2002;187(3):569-574.  https://doi.org/10.1067/mob.2002.125897
  59. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health. 2018; 18(1):94.  https://doi.org/10.1186/s12905-018-0607-z
  60. Yan L, Wang XD, Seyedmousavi S, Yuan JN, Abulize P, Pan WH, Yu N, Yang Y, Hu H, Liao W, Deng S. Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China. Mycopathologia. 2019;184(3):413-422.  https://doi.org/10.1007/s11046-018-0305-2
  61. Arzumanyan VG, Malbakhova ET, Magarshak OO, Osokina OV. Monitoring the effectiveness of natamycin and azoles in vitro in relation to yeast strains isolated from different types of epithelium. Voprosy ginekologii, akusherstva i perinatologii. 2015;14(4):58-63. (In Russ.).
  62. Sadeghi G, Ebrahimi-Rad M, Mousavi SF, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Emergence of non-Candida albicans species: Epidemiology, phylogeny and fluconazole susceptibility profile. Journal de Mycologie Medicale. 2018;28(1):51-58.  https://doi.org/10.1016/j.mycmed.2017.12.008
  63. Brandolt TM, Klafke GB, Gonçalves CV, Bitencourt LR, Martinez AM, Mendes JF, Meireles MC, Xavier MO. Prevalence of Candida spp. in cervical-vaginal samples and the in vitro susceptibility of isolates. Brazilian Journal of Microbiology. 2017;48(1):145-150.  https://doi.org/10.1016/j.bjm.2016.09.006
  64. Tsega A, Mekonnen F. Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia. BMC Pregnancy and Childbirth. 2019; 19(1):527.  https://doi.org/10.1186/s12884-019-2494-1
  65. Rezaei-Matehkolaei A, Shafiei S, Zarei-Mahmoudabadi A. Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species. Iranian Journal of Microbiology. 2016;8(6):410-417. 
  66. Novikova VV, Ezhov SG, Selivanova AI. Analysis of the species composition and sensitivity of Candida spp clinical isolates to modern antimicotics. Medicinskij al’manah. 2017;47(2):138-141. (In Russ.).
  67. Novikova VV, Ezhov SG. Assessment of the Candida spp. composition isolated from various biotopes and their sensitivity to antifungal drugs. RMJ. 2019;27(4):67-71. 
  68. Pashinina OA, Kartashova OL, Pashkova TM, Popova LP. Antimycotic resistance of Candida fungi isolated from the reproductive tract of women with inflammatory diseases of the genitals. Byulleten’ Orenburgskogo nauchnogo centra UrO RAN. 2016;3:2-9. (In Russ).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.